BRAINSWAY LTD/S (NASDAQ:BWAY) issued its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.15), Fidelity Earnings reports. The company had revenue of $4.16 million for the quarter, compared to analyst estimates of $4.00 million. BRAINSWAY LTD/S had a negative return on equity of 45.01% and a negative net margin of 53.74%. BRAINSWAY LTD/S updated its Q2 2020
Pre-Market guidance to EPS.
BRAINSWAY LTD/S stock opened at $6.04 on Friday. BRAINSWAY LTD/S has a 1 year low of $5.10 and a 1 year high of $12.53. The company has a market cap of $66.57 million, a PE ratio of -11.18 and a beta of 0.90. The company’s 50-day moving average is $7.55 and its two-hundred day moving average is $9.11.
Several research analysts recently issued reports on BWAY shares. ValuEngine upgraded shares of BRAINSWAY LTD/S from a “hold” rating to a “buy” rating in a research report on Friday, March 6th. Raymond James reduced their price target on shares of BRAINSWAY LTD/S from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 24th. Oppenheimer reiterated a “buy” rating and set a $13.00 price target on shares of BRAINSWAY LTD/S in a research report on Wednesday. Cantor Fitzgerald cut their target price on shares of BRAINSWAY LTD/S from $17.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 24th. Finally, Zacks Investment Research downgraded shares of BRAINSWAY LTD/S from a “buy” rating to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.69.
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Read More: Example of operating income, EBIT and EBITDA
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.